Nov 16 (Reuters) - Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion in cash to expand the development of treatments for rare blood cancers, the privately held biotech said on Monday.
The move is the latest in a string of acquisitions by the Indianapolis-based pharmaceutical giant as it works to diversify beyond its blockbuster diabetes and weight-loss franchise, the company's primary growth engine.
The Calytrix transaction includes an upfront payment and additional payments tied to clinical trial and regulatory milestones. Calytrix did not disclose the size of the upfront payment or the deal's expected closing date.
Calytrix's lead candidate is an early-stage antibody treatment for essential thrombocythemia and myelofibrosis – rare blood disorders that cause the bone marrow to produce excessive abnormal blood cells.
The deal is expected to strengthen Lilly's footprint in hematology, adding an experimental treatment to a business that already includes the FDA-approved blood cancer medicine Jaypirca.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shailesh Kuber)